Skip main navigation

Advancing Equity in Sudden Cardiac Death Prevention: Beware of Making Assumptions About the Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Black Patients

Originally published 2023;148:253–255
First page image


The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

For Disclosures, see page 255.

Circulation is available at

Correspondence to: Sana M. Al-Khatib, MD, MHS, Duke Clinical Research Institute, 300 Morgan St, Durham, NC 27701. Email


  • 1. Zhao D, Post WS, Blasco-Colmenares E, Cheng A, Zhang Y, Deo R, Pastor-Barriuso R, Michos ED, Sotoodehnia N, Guallar E. Racial differences in sudden cardiac death.Circulation. 2019; 139:1688–1697. doi: 10.1161/CIRCULATIONAHA.118.036553LinkGoogle Scholar
  • 2. Deo R, Safford MM, Khodneva YA, Jannat-Khah DP, Brown TM, Judd SE, McClellan WM, Rhodes JD, Shlipak MG, Soliman EZ, et al. Differences in risk of sudden cardiac death between Blacks and Whites.J Am Coll Cardiol. 2018; 72:2431–2439. doi: 10.1016/j.jacc.2018.08.2173CrossrefMedlineGoogle Scholar
  • 3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.N Engl J Med. 2002; 346:877–883. doi: 10.1056/NEJMoa013474CrossrefMedlineGoogle Scholar
  • 4. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.N Engl J Med. 2005; 352:225–237. doi: 10.1056/NEJMoa043399CrossrefMedlineGoogle Scholar
  • 5. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Circulation. 2018; 138:e272–e391. doi: 10.1161/CIR.0000000000000549LinkGoogle Scholar
  • 6. Thomas KL, Al-Khatib SM, Kelsey RC, Bush H, Brosius L, Velazquez EJ, Peterson ED, Gilliam FR. Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of <or=35%.Am J Cardiol. 2007; 100:924–929. doi: 10.1016/j.amjcard.2007.04.024CrossrefMedlineGoogle Scholar
  • 7. Hernandez AF, Fonarow GC, Liang L, Al-Khatib SM, Curtis LH, LaBresh KA, Yancy CW, Albert NM, Peterson ED. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure.JAMA. 2007; 298:1525–1532. doi: 10.1001/jama.298.13.1525CrossrefMedlineGoogle Scholar
  • 8. Al-Khatib SM, Hellkamp AS, Hernandez AF, Fonarow GC, Thomas KL, Al-Khalidi HR, Heidenreich PA, Hammill S, Yancy C, Peterson ED; Get With the Guidelines Steering Committee and Hospitals. Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time?.Circulation. 2012; 125:1094–1101. doi: 10.1161/CIRCULATIONAHA.111.066605LinkGoogle Scholar
  • 9. Kong MH, Peterson ED, Fonarow GC, Sanders GD, Yancy CW, Russo AM, Curtis AB, Sears SF, Thomas KL, Campbell S, et al. Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies.Am Heart J. 2010; 160:605–618. doi: 10.1016/j.ahj.2010.07.011CrossrefMedlineGoogle Scholar
  • 10. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, et al. Defibrillator implantation in patients with nonischemic systolic heart failure.N Engl J Med. 2016; 375:1221–1230. doi: 10.1056/NEJMoa1608029CrossrefMedlineGoogle Scholar
  • 11. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.Eur Heart J. 2022; 43:3997–4126. doi: 10.1093/eurheartj/ehac262CrossrefMedlineGoogle Scholar
  • 12. Younis A, Ali S, Hsich E, Goldenberg I, McNitt S, Polonsky B, Aktas MK, Kutyifa V, Wazni OM, Zareba W, et al. Arrhythmia and survival outcomes among Black patients and White patients with a primary prevention defibrillator.Circulation. 2023; 148:241–252. doi: 10.1161/CIRCULATION.123.065367LinkGoogle Scholar
  • 13. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.Eur Heart J. 2021; 42:3727–3738. doi: 10.1093/eurheartj/ehab560CrossrefMedlineGoogle Scholar
  • 14. Fernandes GC, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani RD, Myerburg RJ, Goldberger JJ. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials.Heart Rhythm. 2021; 18:1098–1105. doi: 10.1016/j.hrthm.2021.03.028CrossrefMedlineGoogle Scholar
  • 15. Thomas KL, Al-Khatib SM, Kosinski AS, Sears SF, Allen LaPointe NM, Jackson LR, Matlock DD, Haithcock D, Colley BJ, Hirsh DS, et al. Facilitating shared decision making among black patients at risk for sudden cardiac arrest: a randomized clinical trial.Ann Intern Med. 2023; 176:615–623. doi: 10.7326/M22-2934CrossrefMedlineGoogle Scholar


eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.